oregovomab + bevacizumab + paclitaxel + carboplatin

This is a **combination regimen** consisting of *oregovomab* (a monoclonal antibody targeting CA125, used to enhance antitumor immune responses), *bevacizumab* (a monoclonal antibody that inhibits vascular endothelial growth factor [VEGF], reducing angiogenesis), *paclitaxel* (a small molecule antineoplastic agent that stabilizes microtubules, inhibiting cell division), and *carboplatin* (a small molecule platinum analog that crosslinks DNA and induces apoptosis in rapidly proliferating cells). This specific combination has been investigated primarily for **advanced epithelial ovarian cancer**, building on the backbone of carboplatin and paclitaxel, which is standard first-line chemotherapy for this disease[1][2][3][4]. The addition of bevacizumab is considered a form of targeted therapy, and oregovomab represents investigational immunotherapy to further potentiate antitumor effects.

Other names

oregovomab + bevacizumab + paclitaxel + carboplatin